×
Trevena Operating Expenses 2012-2024 | TRVN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Trevena operating expenses from 2012 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Trevena Operating Expenses 2012-2024 | TRVN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Trevena operating expenses from 2012 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$140.4B
Bristol Myers Squibb (BMY)
$114.2B
Gilead Sciences (GILD)
$113.5B
Vertex Pharmaceuticals (VRTX)
$102.1B
CSL (CSLLY)
$83.7B
Regeneron Pharmaceuticals (REGN)
$77.8B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$37.8B
Alnylam Pharmaceuticals (ALNY)
$30.8B
BioNTech SE (BNTX)
$26.5B
Biogen (BIIB)
$21.5B
Illumina (ILMN)
$21.3B
BeiGene (BGNE)
$17B
Moderna (MRNA)
$15.2B
Genmab (GMAB)
$13.3B
Incyte (INCY)
$12.9B
Insmed (INSM)
$12.4B
BioMarin Pharmaceutical (BMRN)
$12.4B
Sarepta Therapeutics (SRPT)
$11.4B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$10.7B
Exact Sciences (EXAS)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.2B
QIAGEN (QGEN)
$10.1B
Exelixis (EXEL)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.9B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8.2B